Education
About Us
Working with TipRanks
Follow Us
Sutro Biopharma Inc (STRO)
NASDAQ:STRO
STRO Stock Chart & Stats
$10.38
-$0.05(-2.48%)
At close: 4:00 PM EST
$10.38
-$0.05(-2.48%)
Day’s Range― - ―
52-Week Range$5.24 - $24.80
Previous CloseN/A
Volume326.60K
Average Volume (3M)987.85K
Market Cap
$88.43M
Enterprise Value$688.40M
Total Cash (Recent Filing)$167.59M
Total Debt (Recent Filing)$17.66M
Price to Earnings (P/E)―
Beta3.91
Next Earnings
Mar 12, 2026EPS Estimate
-8.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.70
Shares Outstanding8,519,392
10 Day Avg. Volume2,002,360
30 Day Avg. Volume987,852
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)31.70
Price to Sales (P/S)22.79
P/FCF Ratio-7.26
Enterprise Value/Market Cap7.78
Enterprise Value/Revenue6.52
Enterprise Value/Gross Profit6.52
Enterprise Value/Ebitda-4.63
Forecast
1Y Price Target
$17.96Price Target Upside73.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsSutro announced that the first cohort of patients has been dosed in the Phase 1 basket trial of STRO-004, marking the formal clinical entry of what management views as a core wholly owned value driver.
Preclinical DataPreclinical data show that STRO-004 achieves substantially higher conjugated payload exposure than approved and emerging exatecan-based ADCs at non-severely toxic doses.
Strategic InitiativesThe initiation of STRO-004 reinforces Sutro’s strategic pivot toward a precision-engineered ADC platform designed to deliver meaningfully higher drug exposure with improved tolerability.
Bears Say
Clinical ExecutionThe focus shifts toward execution, dose optimization, and indication prioritization, raising questions around how quickly the program can reach exposure levels associated with preclinical efficacy.
Competitive DifferentiationSignificant clinical validation is needed to fully understand competitive differentiation despite encouraging preclinical approaches.
Pipeline RisksSutro’s pipeline is still early, and the company is seen as a longer term opportunity for investors who are comfortable underwriting preclinical and early clinical risk.
Sutro Biopharma News
STRO FAQ
What was Sutro Biopharma Inc’s price range in the past 12 months?
Sutro Biopharma Inc lowest stock price was $5.24 and its highest was $24.80 in the past 12 months.
What is Sutro Biopharma Inc’s market cap?
Sutro Biopharma Inc’s market cap is $88.43M.
When is Sutro Biopharma Inc’s upcoming earnings report date?
Sutro Biopharma Inc’s upcoming earnings report date is Mar 12, 2026 which is in 76 days.
How were Sutro Biopharma Inc’s earnings last quarter?
Sutro Biopharma Inc released its earnings results on Nov 06, 2025. The company reported -$6.7 earnings per share for the quarter, missing the consensus estimate of -$3.945 by -$2.755.
Is Sutro Biopharma Inc overvalued?
According to Wall Street analysts Sutro Biopharma Inc’s price is currently Undervalued.
Does Sutro Biopharma Inc pay dividends?
Sutro Biopharma Inc does not currently pay dividends.
What is Sutro Biopharma Inc’s EPS estimate?
Sutro Biopharma Inc’s EPS estimate is -8.15.
How many shares outstanding does Sutro Biopharma Inc have?
Sutro Biopharma Inc has 8,519,392 shares outstanding.
What happened to Sutro Biopharma Inc’s price movement after its last earnings report?
Sutro Biopharma Inc reported an EPS of -$6.7 in its last earnings report, missing expectations of -$3.945. Following the earnings report the stock price went down -13.376%.
Which hedge fund is a major shareholder of Sutro Biopharma Inc?
Currently, no hedge funds are holding shares in STRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sutro Biopharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.96 (73.03% Upside)
$17.96 (73.03% Upside)
Hedge Fund Trend
Increased
By 29.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $79.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.43%
12-Months-Change
Fundamentals
Return on Equity
-1810.01%
Trailing 12-Months
Asset Growth
-46.35%
Trailing 12-Months
Company Description
Sutro Biopharma Inc
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
STRO Stock 12 Month Forecast
Average Price Target
$17.96
▲(73.03% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---